Imagine having clear, easy and most importantly, accurate diagnostic testing for cancer. Israeli company Micromedic is delivering. Micromedic Technologies Ltd. focuses on the development and commercialization of innovative in-vitro cancer diagnostic products and solutions.
The companys portfolio includes state-of-the-art technologies involving gene expression or the process by which information from a gene is used in the synthesis of a functional gene product as well as biomarker testing for early cancer detection and personalized medicine.
Micromedic was founded in Israel with its headquarters in Kiryat Atidim, just outside Tel Aviv. It is a publicly traded company found on the Tel Aviv Stock Exchange and counts numerous doctors, both MD and PhD, as part of their team of experts.
Most recently Micromedic saw its share price soar over 75% following the news of positive results in a trial of its prostate cancer diagnosis solution. This ground breaking test is non-invasive and uses the company’s CellDetect technology. The company believes that having non-invasive tests, such as this one, is likely to help patients avoid unnecessary biopsies, improve many diagnosis of prostate cancer and save hundreds of thousands of dollars in tests.
Micromedic offers proprietary diagnostic solutions for numerous cancer diagnostic applications and provides practical answers to real, unmet needs.